摘要
目的探讨低分子肝素联合华法林对非大面积肺栓塞患者治疗的临床效果。方法非大面积肺栓塞患者64例随机分为观察组与对照组各32例,对照组使用低分子肝素进行治疗,观察组在对照组的基础上,加用华法林进行治疗。评价两组患者的临床疗效,观察并记录两组患者超声心动图指标、动脉血气指标、凝血指标和不良反应情况。结果观察组临床总有效率显著高于对照组(P<0.05);与治疗前相比,治疗后两组患者心动图指标、动脉血气和凝血指标均改善,且观察组改善情况优于对照组,差异具有统计学意义(P<0.05);两组患者不良反应发生率差异没有统计学意义(P>0.05)。结论低分子肝素联合华法林治疗非大面积肺栓塞,患者临床症状明显改善,动脉血气指标、凝血指标和心功能明显好转,且不良反应较小;临床疗效优于低分子肝素治疗。
Objective To understand the clinical efficacy of low molecular weight heparin combined with warfarin in the treatment of non-large area pulmonary embolism. Method 64 cases of non-large-area pulmonary embolism were randomly divided into an experimental group （ n = 32） and a control group （n = 32）. The control group were treated with low molecular weight heparin while the experimental group were treated with a combination of warfarin and low molecular weight heparin. The eehocardiography indicators, the arterial blood gas index, the coagulation index and the adverse reactions as observed in the two groups were then doeumented so as to evaluate the efficacy of the two treatment methods. Findings The total efficacy rate of the experimental group was significantly higher than that of the eontrol group （ P 〈 0.05 ）. Compared with those before treatment, the cardiac index, arterial blood gas and eoagulation index of both groups were improved after treatment, with the improvement in the experimental group being more significant than that of the control group. No significant difference was observed in the incidence of adverse reactions between the two groups （P 〉 0.05）. Conclusion Low molecular weight heparin combined with warfarin proved to be desirable therapy more effieient than low molecular weight heparin in the treatment of non-large area pulmonary embolism. It can address the clinical symptoms more effectively and improve the arterial blood gas index, the coagulation index and the cardiac function more significantly and bring about less adverse reactions.
出处
《健康研究》
CAS
2017年第3期287-289,共3页
Health Research
关键词
低分子肝素
华法林
肺栓塞
临床效果
low molecular weight heparin
warfarin
pulmonary embolism
clinical efficacy
